Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Aminosalicylic acid
Drug ID BADD_D00114
Description An antitubercular agent often administered in association with isoniazid. The sodium salt of the drug is better tolerated than the free acid.
Indications and Usage For the treatment of tuberculosis
Marketing Status approved
ATC Code J04AA01
DrugBank ID DB00233
KEGG ID D00162
MeSH ID D010131
PubChem ID 4649
TTD Drug ID D01WJL
NDC Product Code 76003-0710
UNII 5B2658E0N2
Synonyms Aminosalicylic Acid | Acid, Aminosalicylic | 4-Aminosalicylic Acid | 4 Aminosalicylic Acid | para-Aminosalicylic Acid | para Aminosalicylic Acid | p-Aminosalicylic Acid | p Aminosalicylic Acid | p-Aminosalicylic Acid Monolithium Salt | p Aminosalicylic Acid Monolithium Salt | p-Aminosalicylic Acid Monopotassium Salt | p Aminosalicylic Acid Monopotassium Salt | Rezipas | p-Aminosalicylic Acid, Aluminum (2:1) Salt | p-Aminosalicylic Acid, Calcium (2:1) Salt | p-Aminosalicylic Acid, Monosodium Salt, Dihydrate | Pamisyl | Alumino-4-Aminosalicylic Acid | Alumino 4 Aminosalicylic Acid | p-Aminosalicylic Acid Monosodium Salt | p Aminosalicylic Acid Monosodium Salt
Chemical Information
Molecular Formula C7H7NO3
CAS Registry Number 65-49-6
SMILES C1=CC(=C(C=C1N)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Agranulocytosis01.02.03.001--Not Available
Anaemia01.03.02.001--
Body temperature increased13.15.01.001--Not Available
Coombs positive haemolytic anaemia01.06.01.001; 10.04.01.001--Not Available
Crystalluria20.02.01.003--Not Available
Dermatitis23.03.04.002--Not Available
Dermatitis allergic23.03.04.003; 10.01.03.014--Not Available
Dermatitis atopic10.01.04.004; 23.03.04.016--Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dysgeusia07.14.03.001; 17.02.07.003--
Encephalopathy17.13.02.001--
Flatulence07.01.04.002--
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Gastrointestinal pain07.01.05.005--
Haemolytic anaemia01.06.03.002--Not Available
Headache17.14.01.001--
Hepatitis09.01.07.004--Not Available
Hypersensitivity10.01.03.003--
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hypothyroidism14.11.01.012; 05.02.03.001--
Infectious mononucleosis11.05.10.003; 01.02.01.007--Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Leukopenia01.02.02.001--Not Available
Loeffler's syndrome22.01.01.011; 01.02.04.008--Not Available
Lymphoma01.12.01.001; 16.20.01.001--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene